乳腺癌新辅助化疗中肿瘤标志物检测的临床意义

目的检测肿瘤标志物在新辅助化疗乳腺癌中的表达,探讨新辅助化疗患者中ER、PR、c-erbB2和Ki67的表达及临床意义.方法用免疫组织化学法检测ER、PR、c-erbB2和Ki67在89例新辅助化疗乳腺癌组织中的表达状况,分析上述指标与化疗的关系.结果新辅助化疗总有效率89.9%,其中完全缓解CR32.6%,部分缓解PR57.3%,病理完全缓解pCR17.9%,疾病稳定SD10.5%,无恶化病例.ER/PR表达与疗效有关（P〈0.05）,c-erbB2、Ki67表达与化疗疗程无关.结论激素受体阴性者对新辅助化疗的敏感性较高,新辅助化疗肿瘤标志物的检测可以为临床评价疗效判断预后提供依据.

Clinical significance of tumor markers in neoadjuvant chemotherapy of breast cancer

Objective To explore the expression and its clinical significance of tumor markers in breast cancer tissue received neoadjuvant chemotherapy.Methods The ER,PR,c-erbB2,Ki67 in breast cancer tissue of 89 patients received neoadjuvant chemotherapy were detected by immunohistochemical method,and analysed the relation to tumor markers with response of neoadjuvant chemotherapy.Results The overall response rate of neoadjuvant chemotherapy on breast cancer was 89.9%,of which the complete response was 32.6%,partial response was 57.3%,pathological complete response was 17.9%,disease stable 10.5%.Hormonal receptor expression was significantly related to treatment response(P<0.05).No correlation was observed between the treatment response and c-erB2,Ki67 expression.Conclusion There is higher sensitivity in neoadjuvant chemotherapy hormonal receptor negative tumors.The tumor markers of breast cancer in neoadjuvant chemotherapy may be provide important index in decision sensation of chemotherapy and clinical evaluation.